In 2024, the International Myeloma Society (IMS) and IMWG incorporated chromosomal abnormalities, such as del(17p) and/or TP53 mutation, biallelic del(1p32), and two or more intermediate-risk rearrangements, such as 1q21+, t(4;14), t(14;16), and monoallelic del(1p32), into the MM scoring model, which allowed to classify 20% of newly diagnosed MM (NDMM) patients as high-risk [104]. Here, TP53 is linked to Miyoshi myopathy.